[1] Shiboski CH, Shiboski SC, Seror R, et al.2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome[J]. Ann Rheum Dis, 2017, 76(1): 9-16. [2] Seror R, Bowman SJ, Brito-Zeron P, et al.EULAR Sjögren’s syndrome disease activity index (ESSDAI)[J]. RMD Open, 2015, 1(1): e000022. [3] 张文,厉小梅,徐东,等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志,2020,59(4): 269-276. [4] 张文,陈竹,厉小梅,等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志,2023,62(9): 1059-1067. [5] Trevisani VFM, Pasoto SG, Fernandes MLMS, et al.Recommendations from the Brazilian society of rheumatology for the diagnosis of Sjogren’s syndrome (Part I)[J]. Adv Rheumatol, 2019, 59(1): 58. [6] Jousse-Joulin S, D’Agostino MA, Nicolas C, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjögren’s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise[J]. Ann Rheum Dis, 2019, 78(7): 967-973. [7] Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al.EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies[J]. Ann Rheum Dis, 2020, 79(1): 3-18. [8] 亚洲干眼协会中国分会,海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组,中国医师协会眼科医师分会眼表与干眼学组, 等. 中国干眼专家共识:免疫性疾病相关性干眼(2021年)[J]. 中华眼科杂志,2021,57(12): 898-907. [9] Trevisani VFM, Pugliesi A, Pasoto SG, et al.Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal)[J].Adv Rheumatol,2022,62(1):18. [10] Yueting L, Lin Q, Jian X, et al.Long-term survival analysis of patients with primary Sjögren’s syndrome in China[J]. Int J Rheum Dis, 2024, 27(9): e15284. [11] Lee AS, Scofield RH, Hammitt KM, et al.Consensus guidelines for evaluation and management of pulmonary disease in Sjogren’s[J]. Chest, 2021, 159(2): 683-698. [12] Trevisani VFM, Pinheiro AC, de Magalhães Souza Fialho SC, et al. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian society of rheumatology (hepatic, gastrointestinal and pancreatic)[J]. Adv Rheumatol, 2022, 62(1): 35. [13] Xu D, Fang J, Zhang S, et al.Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial[J]. Rheumatology (Oxford),2024, 63(3): 698-705. [14] Alunno A, Carubbi F, Bartoloni E, et al.The kaleidoscope of neurological manifestations in primary Sjögren’s syndrome[J]. Clin Exp Rheumatol, 2019, 37 Suppl 118(3): 192-198. [15] Pugliesi A, Egypto DCSD, Duffles G,et al.Recommendations on cutaneous and hematological manifestations of Sjögren’s disease by the Brazilian Society of Rheumatology[J]. Adv Rheumatol, 2024, 64(1): 51. [16] 中华中医药学会风湿病分会. 干燥综合征病证结合诊疗指南[J]. 中医杂志,2024,65(4): 434-444. [17] Baldini C, Fulvio G, La Rocca G, et al.Update on the pathophysiology and treatment of primary Sjögren syndrome[J]. Nat Rev Rheumatol, 2024, 20(8): 473-491. |